A Trial to Test Intermittent Deep Brain Stimulation of Nucleus Basalis of Meynert to Treat Alzheimers.

Inclusion Criteria:

• Age:65 minimum

• Age:85 maximum

• Probable, early-stage Alzheimer's Disease, as defined by NIA-AA 2018 criteriaand positive PET for beta amyloid,

• no Lewy-Body-dementia or other form of dementia

• Clinical Dementia Rating (CDR) global score of 0.5-1.0 with a CBR-sb score from 2 to 6.

• MMSE ≥ 21

• stable psychopharmacological medication equivalent to 10 mg/day donepezil orless for at least 60 days

• valid informed consent

• an available caregiver willing to participate

• subject is living at home and likely to remain at home for the study duration

• Geriatric Depression Scale of 5 or less

• Columbia Suicide Severity Rating Scale "No" on questions 3 through 5

• Neuropsychiatric Inventory (NPI-Q) under 2 on 'Delusions', 'Hallucinations' or 'Agitation/Aggression' subscales

Exclusion Criteria:

• • clinical co-morbidity interfering with study (e.g. head trauma requiring medicaltreatment in the 2 years prior, brain tumor, subdural hematoma, or other clinicallysignificant space-occupying lesion on brain CT or MRI), or other implant precludinghigh field MRI scans.

• current major psychiatric disorder such as schizophrenia, bipolar disorder ormajor depressive disorder based on psychiatric consult at screening visit, orpast medical history prior suicidal attempts or suicidal crises

• Another concurrent CNS condition (ie, stroke, Parkinson's disease, Lewy-Bodydementia or other form of dementia, other evidence of significant structuralbrain pathology).

• Medical history of seizure disorder including epilepsy

• Terminal illness associated with expected survival of <30 months

• Subjects with one of these other forms of dementia in the DSM-5 heading ofNeurocognitive Disorders: Lewy body disease, Frontotemporal lobar degeneration,Vascular disease, Traumatic brain injury, HIV infection, Prion disease,Parkinson's disease, Huntington's disease, or due to multiple etiologies

• Subjects with unstable medical and neurological conditions at the discretion ofthe Principle Investigator